etranacogene dezaparvovec

AXP000253.1 · Viral vector gene therapy

Platform
AAV5 vector
Targets
F9
Originator
uniQure
Sponsor
CSL Behring

Names

NameTypeSource
etranacogene dezaparvovecpreferred namecurator
Hemgenixbrandfda
AMT-061former codecurator

Virus

Role
In vivo gene transfer
Family
Parvoviridae
Virus
adeno-associated virus 5
Strain
AAV5
Replication
non replicating
Modifications
liver-specific LP1 promoter
Transgenes
F9 (R338L Padua variant)
Route
intravenous
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2022-11-22approvedHemgenixAdults with haemophilia B on factor IX prophylaxis, or with life-threatening or repeated serious spontaneous bleeding; anti-AAV5 titre below 1:700source
EMAEU2023-02-20conditionalHemgenixSevere and moderately severe haemophilia Bsource

Clinical trials (6)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07080905Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia BRecruitingPhase 32025-07-282033-10-2420Hemophilia B
NCT06003387Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)RecruitingPhase 32024-01-302028-10-0435Hemophilia B
NCT05962398Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)Enrolling by invitation2023-08-302035-03-2356Hemophilia B
NCT06008938An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BRecruiting2023-06-152043-08-01500Hemophilia B
NCT03489291Dose Confirmation Trial of AAV5-hFIXco-PaduaCompletedPhase 22018-07-242018-10-303Hemophilia B
NCT03569891HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B PatientsCompletedPhase 32018-06-272021-09-2267Hemophilia B

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41358585Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.The New England journal of medicine2026cited by trial NCT03569891
PMID 39341368Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B.Journal of thrombosis and haemostasis : JTH2025cited by trial NCT03489291
PMID 39935281Mutagenesis and Carcinogenesis Risk Evaluation for AAV and Lentiviral Gene Therapies.International journal of toxicology2025cited by trial NCT03569891
PMID 40188458Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years.Blood advances2025cited by trial NCT03489291
PMID 38437857Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.The Lancet. Haematology2024cited by trial NCT03569891
PMID 38462823Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy.Haemophilia : the official journal of the World Federation of Hemophilia2024name in title: etranacogene dezaparvovec
PMID 36490302Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy.Blood advances2023cited by trial NCT03489291
PMID 36812434Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.The New England journal of medicine2023cited by trial NCT03569891
PMID 31698454Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.Blood advances2019cited by trial NCT03489291

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40785174A Paradigm Shift in Hemophilia Care: The Promise of Gene Therapy.Current gene therapy2026name in abstract: etranacogene dezaparvovec
PMID 41274843Long-term durability of rAAV gene therapy in hemophilia: Factor expression, clinical outcomes and underlying molecular mechanisms.Blood reviews2026name in abstract: etranacogene dezaparvovec
PMID 41381305Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies.Blood reviews2026name in abstract: etranacogene dezaparvovec
PMID 41448545Overview of gene therapy for hemophilia: questions and answers to navigate the innovation.Journal of thrombosis and haemostasis : JTH2026name in abstract: etranacogene dezaparvovec
PMID 41496894CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges.Molecular therapy. Nucleic acids2026name in abstract: Hemgenix
PMID 41549917Balancing Promise and Peril: Hemophilia Gene Therapy Insights.IUBMB life2026name in abstract: etranacogene dezaparvovec
PMID 41624239Etranacogene dezaparvovec in people with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: a 4-year subgroup analysis of the Health Outcomes with Padua Gene; Evaluation in Hemophilia B (HOPE-B) trial.Research and practice in thrombosis and haemostasis2026name in title: etranacogene dezaparvovec
PMID 41756540Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial.Research and practice in thrombosis and haemostasis2026name in title: etranacogene dezaparvovec
PMID 41773269Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders.Journal of blood medicine2026name in abstract: etranacogene dezaparvovec
PMID 41938187Signals of Toxicity Associated With Gene Therapy: The Case of Etranacogene Dezaparvovec in the Treatment of Hemophilia B.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians2026name in title: etranacogene dezaparvovec
PMID 41988906Bringing Gene Therapy Into Real World Clinical Practice.Haemophilia : the official journal of the World Federation of Hemophilia2026name in abstract: etranacogene dezaparvovec
PMID 42322300Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec.CPT: pharmacometrics & systems pharmacology2026name in title: etranacogene dezaparvovec
PMID 42432779Vulnerability, protection and fairness: ethical and regulatory limits in small-N gene therapy trials.Trials2026name in abstract: Hemgenix
PMID 42459106Etranacogene dezaparvovec in hemophilia B: early safety insights.Recenti progressi in medicina2026name in title: etranacogene dezaparvovec
PMID 42509646Correction to "Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec".CPT: pharmacometrics & systems pharmacology2026name in title: etranacogene dezaparvovec
PMID 42676001Bridging the Gap: A Systematic Review of Modern Hemophilia Therapies and Global Inequities in Clinical Trial Participation.Haemophilia : the official journal of the World Federation of Hemophilia2026name in abstract: etranacogene dezaparvovec
PMID 42750232Treatment With Etranacogene Dezaparvovec in a Renal Transplant Recipient With Hemophilia B on Concomitant Systemic Immunosuppressive Therapy.Haemophilia : the official journal of the World Federation of Hemophilia2026name in title: etranacogene dezaparvovec
PMID 42762467Biphasic Transaminitis During Corticosteroid Tapering After Etranacogene Dezaparvovec Gene Therapy for Haemophilia B: Management Lessons From the First Spanish Case.Haemophilia : the official journal of the World Federation of Hemophilia2026name in title: etranacogene dezaparvovec
PMID 42829928Cost-effectiveness of etranacogene dezaparvovec compared to eftrenonacog alfa for the treatment of adult patients with severe and moderately severe haemophilia B in Sweden.Journal of medical economics2026name in title: etranacogene dezaparvovec
PMID 42830788Corrigendum to 'Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial': [RPTH, 103360, January 2026, Volume 10, Issue 1].Research and practice in thrombosis and haemostasis2026name in title: etranacogene dezaparvovec
PMID 42837422The Genomic Equity Accessibility Framework (GEAF): A dimensionally consistent framework for modeling affordability and equity in genomic and regenerative therapies.PloS one2026name in abstract: Hemgenix
PMID 42932029Financing High-Cost Gene Therapy Under Clinical Uncertainty: Assessing Budget Impact of Reimbursement Models for Hemgenix® in Hemophilia B in Sweden.Applied health economics and health policy2026name in title: Hemgenix
PMID 42947409Arthroplasty After Hemophilia Gene Therapy: Perioperative Implications and Clinical Experience.Haemophilia : the official journal of the World Federation of Hemophilia2026name in abstract: etranacogene dezaparvovec
PMID 42976908Patient-Relevant Questions on Gene Therapy for Haemophilia.Hamostaseologie2026name in abstract: etranacogene dezaparvovec
PMID 42984386Adeno-associated virus gene therapy for hemophilia B: a comparative appraisal of the licensed products.Haematologica2026name in abstract: etranacogene dezaparvovec
PMID 39368017Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability.PharmacoEconomics2025name in abstract: etranacogene dezaparvovec
PMID 39623116Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA.Applied health economics and health policy2025name in title: etranacogene dezaparvovec
PMID 39868419Gene-ius at work: Hemophilia B treatment enters a new era.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2025name in abstract: etranacogene dezaparvovec
PMID 40156191The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy2025name in abstract: etranacogene dezaparvovec
PMID 40488175Gene-based therapies for hemophilia.Research and practice in thrombosis and haemostasis2025name in abstract: etranacogene dezaparvovec
PMID 40534246Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy.Haemophilia : the official journal of the World Federation of Hemophilia2025name in title: etranacogene dezaparvovec
PMID 40868273Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context.Biomedicines2025name in abstract: Hemgenix
PMID 40916408Advances in Gene Therapy Clinical Trials for Hemophilia Care.Current gene therapy2025name in abstract: etranacogene dezaparvovec
PMID 40969675Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study.Molecular therapy. Methods & clinical development2025name in title: etranacogene dezaparvovec
PMID 41229950Role of Pharmacy Professionals in Gene Therapy Based on Adeno-Associated Viruses: Treatment of Hemophilia as a Template of Care.The Canadian journal of hospital pharmacy2025name in abstract: etranacogene dezaparvovec
PMID 41348030Deconstructing gene therapy in hemophilia for the clinician.Hematology. American Society of Hematology. Education Program2025name in abstract: etranacogene dezaparvovec
PMID 37902714Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B.Haemophilia : the official journal of the World Federation of Hemophilia2024name in title: etranacogene dezaparvovec
PMID 37978816Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B.The Annals of pharmacotherapy2024name in abstract: Hemgenix
PMID 37989969Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid.PharmacoEconomics2024name in abstract: etranacogene dezaparvovec
PMID 38384245Recent developments in gene therapy research in India.Journal of biosciences2024name in abstract: Hemgenix
PMID 38520664Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany.PharmacoEconomics - open2024name in title: etranacogene dezaparvovec
PMID 38592711Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec.Blood advances2024name in title: etranacogene dezaparvovec
PMID 38625717Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.Journal of managed care & specialty pharmacy2024name in title: etranacogene dezaparvovec
PMID 38708771Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.Journal of medical economics2024name in title: etranacogene dezaparvovec
PMID 38830504Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity.Drug discovery today2024name in abstract: etranacogene dezaparvovec
PMID 38995136[Haemophilia B therapy: impact of the reimbursability of a long-acting recombinant factor on pharmaceutical expenditure in Italy].Epidemiologia e prevenzione2024name in abstract: etranacogene dezaparvovec
PMID 39088338The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B.Journal of managed care & specialty pharmacy2024name in title: etranacogene dezaparvovec
PMID 39173877Gene therapy for people with hemophilia B: a proposed care delivery model in Italy.Journal of thrombosis and haemostasis : JTH2024name in abstract: etranacogene dezaparvovec
PMID 39339243Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B.Pharmaceutics2024name in abstract: etranacogene dezaparvovec
PMID 39340327Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi-criteria decision analysis.Haemophilia : the official journal of the World Federation of Hemophilia2024name in title: etranacogene dezaparvovec
PMID 36285399Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.Current medical research and opinion2023name in title: etranacogene dezaparvovec
PMID 36651790Hemgenix - A gene therapy for hemophilia B.The Medical letter on drugs and therapeutics2023name in title: Hemgenix
PMID 36774218New Drug Capsule: etranacogene dezaparvovec.Clinical therapeutics2023name in title: etranacogene dezaparvovec
PMID 36799758[A long-awaited - but prohibitively expensive - therapy].Medecine sciences : M/S2023name in abstract: Hemgenix
PMID 36802324Etranacogene Dezaparvovec: First Approval.Drugs2023name in title: etranacogene dezaparvovec
PMID 37353081Hemophilia gene therapy: first, do no harm.Journal of thrombosis and haemostasis : JTH2023name in abstract: etranacogene dezaparvovec
PMID 37490225Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2023name in abstract: etranacogene dezaparvovec
PMID 37672530Hemophilia Gene Therapy: The End of the Beginning?Human gene therapy2023name in abstract: etranacogene dezaparvovec
PMID 37882214Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.Expert review of hematology2023name in title: etranacogene dezaparvovec
PMID 37962325Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency).Expert opinion on biological therapy2023name in title: etranacogene dezaparvovec
PMID 38462459Viral Vectors in Gene Replacement Therapy.Biochemistry. Biokhimiia2023name in abstract: Hemgenix
PMID 36082993Liver Gene Therapy.Human gene therapy2022name in abstract: etranacogene dezaparvovec
PMID 36485127Gene therapy for hemophilia.Hematology. American Society of Hematology. Education Program2022name in abstract: etranacogene dezaparvovec
PMID 37181105Etranacogene dezaparvovec for hemophilia B gene therapy.Therapeutic advances in rare disease2021name in title: etranacogene dezaparvovec
PMID 32777062Von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019;3(21):3241-3247.Blood advances2020name in title: etranacogene dezaparvovec
PMID 31276009Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs.Molecular therapy. Methods & clinical development2019name in abstract: AMT-061
PMID 31709273Enhanced Factor IX Activity following Administration of AAV5-R338L "Padua" Factor IX versus AAV5 WT Human Factor IX in NHPs.Molecular therapy. Methods & clinical development2019name in abstract: AMT-061

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01HL177230Capsid- and genome-modified AAV3 vectors for hemophilia gene therapy.UNIVERSITY OF FLORIDASRIVASTAVA, ARUN2025–2026name in abstract: Hemgenix

Notes

AAV5 vector carrying a codon-optimised factor IX Padua (R338L) cDNA under the liver-specific LP1 promoter, for haemophilia B. US label restricts use to patients with a pre-existing neutralising anti-AAV5 titre below 1:700.

How to cite

etranacogene dezaparvovec (AXP000253.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000253.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.